Recorded fact · drug.label_indication
drug.label_indication for semaglutide|chronic-kidney-disease
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact f12b376e resolves to.
The record
| Fact id | f12b376eff5d78374f1b1564 |
|---|---|
| Entity | drug: semaglutide|chronic-kidney-disease |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260730 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 6079e835dc692b504d7cf07b902cfba418267fbf46a17171a35da861a14ad7b7.
The value
{
"ingredient": "SEMAGLUTIDE",
"conditionId": "chronic-kidney-disease",
"conditionName": "Chronic Kidney Disease",
"matchedAlias": "chronic kidney disease",
"context": "risk-reduction",
"brand": "Ozempic",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "42bdd912-2393-44c4-b7e0-47672ca28991",
"labelEffectiveTime": "20260730",
"labelsRead": 4,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: cbe8b20c2df78cd3173b6792a3af5c72ac523420a27dace886826faeba49249e.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.